Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes
详细信息 查看全文
- 作者：Talha Badara ; Keyur P. Patelb ; Philip A. Thompsona ; Courtney DiNardoa ; Koichi Takahashia ; Monica Cabreroa ; Gautam Borthakura ; Jorge Cortesa ; Marina Konoplevaa ; Tapan Kadiaa ; Zach Bohannana ; Sherry Piercea ; Elias J. Jabboura ; Farhad Ravandia ; Naval Davera ; Raja Luthrab ; Hagop Kantarjiana ; Guillermo Garcia-Maneroa ; ggarciam@mdanderson.org" class="auth_mail" title="E-mail the corresponding author
- 关键词：MDS ; AML ; Leukemic transformation ; FLT3-ITD ; RAS
- 刊名：Leukemia Research
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：39
- 期：12
- 页码：1367-1374
- 全文大小：975 K
文摘
- •
Twenty six percent acquired FLT3 or RAS mutation at transformation from MDS to AML.
- •
FLT3 and RAS mutation acquisition were independent predictor of poor prognosis.
- •
Monitoring FLT3 and RAS at transformation to AML has important prognostic and therapeutic value.